Prevalence and causes of chronic cough in Japan
- PMID: 38522360
- DOI: 10.1016/j.resinv.2024.02.017
Prevalence and causes of chronic cough in Japan
Abstract
Background: Chronic cough is one of the most common symptoms of respiratory diseases and can adversely affect patients' quality of life and interfere with social activities, resulting in a significant social burden. A survey is required to elucidate the frequency and treatment effect of chronic cough. However, clinical studies that cover all of Japan have not yet been conducted.
Methods: Patients who presented with a cough that lasted longer than 8 weeks and visited the respiratory clinics or hospitals affiliated with the Japan Cough Society during the 2-year study period were registered.
Results: A total of 379 patients were enrolled, and those who did not meet the definition of chronic cough were excluded. A total of 334 patients were analyzed: 201 patients had a single cause, and 113 patients had two or more causes. The main causative diseases were cough variant asthma in 92 patients, sinobronchial syndrome (SBS) in 36 patients, atopic cough in 31 patients, and gastroesophageal reflux (GER)-associated cough in 10 patients. The time required to treat undiagnosed patients and those with SBS was significantly longer and the treatment success rate for GER-associated cough was considerably poor.
Conclusions: We confirmed that the main causes of chronic cough were cough variant asthma, SBS, atopic cough, and their complications. We also showed that complicated GER-associated cough was more likely to become refractory. This is the first nationwide study in Japan of the causes and treatment effects of chronic cough.
Keywords: Atopic cough; Chronic cough; Cough variant asthma; Refractory chronic cough; Unexplained chronic cough.
Copyright © 2024 The Author. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest JH received honoraria from AstraZeneca Pharmaceuticals, United Kingdom; GlaxoSmithKline Pharmaceuticals, United Kingdom. SH received honoraria from AstraZeneca Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Kyorin Pharmaceuticals, Japan; Novartis Pharmaceuticals, Switzerland. NO received honoraria from AstraZeneca Pharmaceuticals and research funding from Konica Minolta K.K, Japan. HT received honoraria from AstraZeneca Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Kyorin Pharmaceuticals, Novartis Pharmaceuticals. TY received honoraria from Mitsubishi Tanabe Pharmaceuticals, Japan; Sanofi Pharmaceuticals, France; Kyorin Pharmaceuticals. TN received honoraria from AstraZeneca Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Kyorin Pharmaceuticals, Novartis Pharmaceuticals, Sanofi Pharmaceuticals. HiSag received honoraria from AstraZeneca Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Kracie Pharmaceuticals, Japan; Kyorin Pharmaceuticals, Novartis Pharmaceuticals, Sanofi Pharmaceuticals. HM received honoraria from Kyorin Pharmaceuticals. AN received honoraria from AstraZeneca Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Kyorin Pharmaceuticals, Novartis Pharmaceuticals, Sanofi Pharmaceuticals. The rest of the authors have no conflicts of interest.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical